Skip to main content

BICYCLE THERAPEUTICS PLC

For the period ended Mar 31, 2026. Filed Apr 30, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed Apr 30, 2026

BCYC$3.69-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(In thousands)

​​​​​​​
​ · ​ · Three Months Ended
​ · ​ · March 31,
​ · ​ ​ ​ · 2026 · ​ ​ ​ · 2025
Cash flows from operating activities: · ​ · ​ · ​ · ​ · ​
Net loss​$(60,825)​$(60,754)
Adjustments to reconcile net loss to net cash used in operating activities:​​​​
Share-based compensation expense​6,930​9,605
Depreciation and amortization​1,129​1,634
Deferred income tax benefit​(241)​​(1,316)
Changes in operating assets and liabilities:​​​​​
Accounts receivable​—​(133)
Research and development incentives receivable​(6,040)​(9,278)
Prepaid expenses and other assets​191​(2,968)
Operating lease right‑of‑use assets​1,111​1,089
Accounts payable​(3,838)​(5,019)
Accrued expenses and other current liabilities​(2,353)​(8,208)
Operating lease liabilities​(1,283)​(1,295)
Deferred revenue​(706)​(9,727)
Net cash used in operating activities​(65,925)​(86,370)
Cash flows from investing activities:​​​​
Purchases of property and equipment​(713)​(604)
Net cash used in investing activities​(713)​(604)
Cash flows from financing activities:​​​​
Proceeds from the exercise of share options and settlement of restricted share units​​12​​2
Payments of finance lease obligations​​(66)​​(43)
Net cash used in financing activities​(54)​(41)
Effect of exchange rate changes on cash, cash equivalents and restricted cash​(1,944)​468
Net decrease in cash, cash equivalents and restricted cash​(68,636)​(86,547)
Cash, cash equivalents and restricted cash at beginning of period​628,715​880,067
Cash, cash equivalents and restricted cash at end of period​$560,079​$793,520
Reconciliation of cash, cash equivalents and restricted cash​​​​​​
Cash and cash equivalents​$559,474​$792,973
Restricted cash in prepaid expenses and other current assets​​547​​—
Restricted cash in other assets​​58​​547
Total cash, cash equivalents and restricted cash​$560,079​$793,520
Supplemental disclosure of cash flow information​​​​
Cash paid for interest on finance lease obligations​$26​$22
Cash paid for amounts included in the measurement of operating lease liabilities​$1,525​$1,454
Changes in purchases of property and equipment in accounts payable and accrued expenses​$223​$—
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.